CY1123427T1 - Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn - Google Patents

Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn

Info

Publication number
CY1123427T1
CY1123427T1 CY20201100901T CY201100901T CY1123427T1 CY 1123427 T1 CY1123427 T1 CY 1123427T1 CY 20201100901 T CY20201100901 T CY 20201100901T CY 201100901 T CY201100901 T CY 201100901T CY 1123427 T1 CY1123427 T1 CY 1123427T1
Authority
CY
Cyprus
Prior art keywords
androgen receptor
pystallic
pylodoxea
mophes
andpogonon
Prior art date
Application number
CY20201100901T
Other languages
English (en)
Inventor
Anna Dilhas
Ouathek Ouerfelli
Nicholas D. Smith
Mark R. Herbert
Original Assignee
Aragon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123427(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals, Inc. filed Critical Aragon Pharmaceuticals, Inc.
Publication of CY1123427T1 publication Critical patent/CY1123427T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Στο παρόν περιγράφονται άμορφες και κρυσταλλικές μορφές του διαμορφωτή υποδοχέα ανδρογόνων 4-[7-(6-κυανο-5-τριφθορομεθυλοπυριδιν-3-υλο)-8-οξο-6-θειοξο-5,7-διαζασπιρο[3.4]οκτ-5-υλο]-2-φθορο-Ν-μεθυλοβενζαμίδιο. Επίσης περιγράφονται φαρμακευτικές συνθέσεις κατάλληλες για χορήγηση σε ένα θηλαστικό οι οποίες περιλαμβάνουν το διαμορφωτή υποδοχέα ανδρογόνων, και μέθοδοι χρήσης του διαμορφωτή υποδοχέα ανδρογόνων, μόνου και σε συνδυασμό με άλλες ενώσεις, για την αγωγή νόσων ή παθήσεων που σχετίζονται με την δραστικότητα του υποδοχέα ανδρογόνων.
CY20201100901T 2012-06-07 2020-09-23 Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn CY1123427T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
PCT/US2013/044116 WO2013184681A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator
EP13800681.2A EP2858985B1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number Publication Date
CY1123427T1 true CY1123427T1 (el) 2021-12-31

Family

ID=49712550

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20181100712T CY1120393T1 (el) 2012-06-07 2018-07-06 Κρυσταλλικες μορφες διαμορφωτη υποδοχεα ανδρογονων
CY20201100901T CY1123427T1 (el) 2012-06-07 2020-09-23 Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn
CY20211100595T CY1124831T1 (el) 2012-06-07 2021-07-02 Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181100712T CY1120393T1 (el) 2012-06-07 2018-07-06 Κρυσταλλικες μορφες διαμορφωτη υποδοχεα ανδρογονων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100595T CY1124831T1 (el) 2012-06-07 2021-07-02 Κρυσταλλiκες μορφες διαμορφωτη υποδοχεα ανδρογονων

Country Status (42)

Country Link
US (8) US9481663B2 (el)
EP (4) EP3922629A1 (el)
JP (3) JP6182209B2 (el)
KR (2) KR102195916B1 (el)
CN (3) CN105693692A (el)
AU (3) AU2013271751B2 (el)
BR (1) BR112014030678A2 (el)
CA (4) CA2875767C (el)
CL (1) CL2014003331A1 (el)
CO (1) CO7240407A2 (el)
CR (2) CR20190331A (el)
CY (3) CY1120393T1 (el)
DK (3) DK2858985T3 (el)
EA (3) EA028791B1 (el)
EC (1) ECSP14030098A (el)
ES (3) ES2875932T3 (el)
FR (1) FR21C1050I2 (el)
GT (1) GT201400283A (el)
HK (2) HK1210175A1 (el)
HR (3) HRP20180902T1 (el)
HU (4) HUE054595T2 (el)
IL (4) IL236055A0 (el)
IN (1) IN2014DN10084A (el)
LT (4) LT2858985T (el)
ME (2) ME03815B (el)
MX (1) MX356754B (el)
MY (1) MY187500A (el)
NI (1) NI201400142A (el)
NO (1) NO2021046I1 (el)
NZ (2) NZ702203A (el)
PE (2) PE20150631A1 (el)
PH (2) PH12014502714B1 (el)
PL (3) PL3533792T3 (el)
PT (3) PT2858985T (el)
RS (3) RS61988B1 (el)
SG (3) SG10201610248SA (el)
SI (3) SI2858985T1 (el)
TR (1) TR201808939T4 (el)
TW (1) TWI532732B (el)
UA (2) UA123142C2 (el)
WO (1) WO2013184681A1 (el)
ZA (1) ZA201500076B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2385960B1 (en) 2009-01-12 2020-03-11 University Of Massachusetts Lowell Polyisobutylene-based polyurethanes
KR20140103335A (ko) 2011-12-16 2014-08-26 올레마 파마슈티컬스 인코포레이티드 신규한 벤조피란 화합물, 조성물 및 이의 용도
EA028791B1 (ru) 2012-06-07 2017-12-29 Арагон Фармасьютикалз, Инк. Кристаллическая форма модулятора андрогенных рецепторов
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
BR112015006705A8 (pt) 2012-09-26 2019-08-27 Aragon Pharmaceuticals Inc antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático e usos destes
EP2922888B1 (en) 2012-11-21 2021-08-18 The University of Massachusetts High strength polyisobutylene polyurethanes
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
JP2017525727A (ja) * 2014-08-26 2017-09-07 アスター バイオテック リミテッド ライアビリティ カンパニー プロテインキナーゼ阻害剤
PL3226842T3 (pl) 2014-12-05 2021-07-12 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
MA41107A (fr) 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
ES2883187T3 (es) 2014-12-05 2021-12-07 Aragon Pharmaceuticals Inc Composiciones anticancerosas
CA3091108A1 (en) 2014-12-19 2016-06-23 Lutron Technology Company Llc Multi-channel lighting fixture having multiple light-emitting diode drivers
BR112018074965A2 (pt) 2016-06-03 2019-03-12 Aragon Pharmaceuticals, Inc. composições anticancerígenas
ES2952770T3 (es) 2016-12-13 2023-11-06 Watson Lab Inc Formas de estado sólido de apalutamida
WO2018165273A1 (en) 2017-03-07 2018-09-13 Cardiac Pacemakers, Inc. Hydroboration/oxidation of allyl-terminated polyisobutylene
EP3668912B1 (en) 2017-08-17 2021-06-30 Cardiac Pacemakers, Inc. Photocrosslinked polymers for enhanced durability
CA3079135A1 (en) 2017-10-16 2019-04-25 Arturo Molina Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019135254A1 (en) * 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
CN111479596B (zh) 2018-01-17 2023-04-07 心脏起搏器股份公司 封端聚异丁烯聚氨酯
US20200270226A1 (en) 2018-06-20 2020-08-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of arn-509, preparation method and use thereof
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) * 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
US20220281836A1 (en) * 2019-08-22 2022-09-08 Dr. Reddy's Laboratories Limited Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
EP4208451A1 (en) 2020-09-04 2023-07-12 Synthon B.V. Improved process for preparation of apalutamide
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634A (zh) * 2022-10-17 2022-12-30 上海博悦生物科技有限公司 一种阿帕他胺的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
HUE053877T2 (hu) * 2006-03-27 2021-07-28 Univ California Androgén receptormodulátor a prosztatarák és az androgén receptorral összefüggõ betegségek kezeléséhez
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
CN106983749A (zh) * 2010-02-16 2017-07-28 亚拉冈制药公司 雄激素受体调节剂及其用途
EA028791B1 (ru) 2012-06-07 2017-12-29 Арагон Фармасьютикалз, Инк. Кристаллическая форма модулятора андрогенных рецепторов
US20200270226A1 (en) 2018-06-20 2020-08-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of arn-509, preparation method and use thereof

Also Published As

Publication number Publication date
HRP20201387T1 (hr) 2020-11-27
EA028791B1 (ru) 2017-12-29
NZ717683A (en) 2018-04-27
US9481663B2 (en) 2016-11-01
ME03081B (me) 2019-01-20
KR20190132543A (ko) 2019-11-27
EP2858985B1 (en) 2018-04-18
US20200115361A1 (en) 2020-04-16
LT2858985T (lt) 2018-09-25
SI2858985T1 (sl) 2018-12-31
AU2013271751B2 (en) 2017-02-23
US20190241539A1 (en) 2019-08-08
CR20190331A (es) 2019-11-12
PL2858985T3 (pl) 2018-09-28
RS57370B1 (sr) 2018-08-31
CN113135892A (zh) 2021-07-20
JP2015518890A (ja) 2015-07-06
ES2809738T3 (es) 2021-03-05
AU2017279807A1 (en) 2018-01-25
CA3114726A1 (en) 2013-12-12
SG10201610249TA (en) 2017-02-27
US10766875B2 (en) 2020-09-08
CY1120393T1 (el) 2019-07-10
IL275413A (en) 2020-07-30
AU2017200298A1 (en) 2017-02-02
CY1124831T1 (el) 2022-03-24
EP3922629A1 (en) 2021-12-15
CN105693692A (zh) 2016-06-22
UA123142C2 (uk) 2021-02-24
LTPA2021525I1 (el) 2021-11-25
CR20140549A (es) 2015-04-06
CA3008345A1 (en) 2013-12-12
US20150133481A1 (en) 2015-05-14
GT201400283A (es) 2017-07-03
HK1210175A1 (en) 2016-04-15
EA201492272A1 (ru) 2015-05-29
SI3348553T1 (sl) 2020-11-30
US10556882B2 (en) 2020-02-11
IL267608A (en) 2019-08-29
JP6345821B2 (ja) 2018-06-20
PT2858985T (pt) 2018-07-10
CA2875767C (en) 2018-08-14
KR102062024B1 (ko) 2020-01-03
HUE050357T2 (hu) 2020-11-30
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
CO7240407A2 (es) 2015-04-17
ZA201500076B (en) 2016-10-26
SI3533792T1 (sl) 2021-11-30
EA033956B1 (ru) 2019-12-13
AU2017279807B2 (en) 2018-11-08
US20200354335A1 (en) 2020-11-12
WO2013184681A1 (en) 2013-12-12
US20210163441A1 (en) 2021-06-03
HUE054595T2 (hu) 2021-09-28
PH12014502714A1 (en) 2015-02-02
AU2013271751A1 (en) 2014-12-18
LT3348553T (lt) 2020-09-25
HRP20210909T1 (hr) 2021-09-03
SG10201610248SA (en) 2017-02-27
US20180258067A1 (en) 2018-09-13
US10308630B2 (en) 2019-06-04
EP3533792A1 (en) 2019-09-04
PL3348553T3 (pl) 2021-02-08
CA2875767A1 (en) 2013-12-12
ECSP14030098A (es) 2016-01-29
ES2875932T3 (es) 2021-11-11
PH12014502714B1 (en) 2015-02-02
EA201992010A1 (ru) 2020-01-24
FR21C1050I1 (fr) 2021-12-10
JP2017178923A (ja) 2017-10-05
IN2014DN10084A (el) 2015-08-21
HRP20180902T1 (hr) 2018-08-24
MX356754B (es) 2018-06-11
MY187500A (en) 2021-09-24
EP3348553B1 (en) 2020-07-08
KR20150021993A (ko) 2015-03-03
UA115665C2 (uk) 2017-12-11
IL259738B (en) 2021-06-30
DK3533792T3 (da) 2021-06-28
PT3348553T (pt) 2020-09-28
MX2014015005A (es) 2015-09-04
PE20150631A1 (es) 2015-05-11
SG11201408140QA (en) 2015-01-29
EA201791592A1 (ru) 2018-01-31
BR112014030678A2 (pt) 2017-06-27
EP3533792B1 (en) 2021-05-05
RS61988B1 (sr) 2021-07-30
US20190330182A1 (en) 2019-10-31
LT3533792T (lt) 2021-07-26
IL236055A0 (en) 2015-02-01
FR21C1050I2 (fr) 2024-05-24
PT3533792T (pt) 2021-06-07
JP2018141009A (ja) 2018-09-13
EP2858985A1 (en) 2015-04-15
NO2021046I1 (no) 2021-11-02
US9994545B2 (en) 2018-06-12
ME03815B (me) 2021-04-20
CA3008345C (en) 2019-10-22
TR201808939T4 (tr) 2018-07-23
CN104619692A (zh) 2015-05-13
KR102195916B1 (ko) 2020-12-30
PH12016501470B1 (en) 2017-07-10
PL3533792T3 (pl) 2021-11-29
PH12016501470A1 (en) 2017-07-10
NZ702203A (en) 2016-09-30
TWI532732B (zh) 2016-05-11
EP2858985A4 (en) 2016-05-25
ES2670683T3 (es) 2018-05-31
PE20200725A1 (es) 2020-07-21
CL2014003331A1 (es) 2016-03-04
HUS2100047I1 (hu) 2021-11-29
EP3348553A1 (en) 2018-07-18
AU2017200298B2 (en) 2017-09-28
HUE038082T2 (hu) 2018-09-28
TW201402561A (zh) 2014-01-16
US10526310B2 (en) 2020-01-07
US20170001977A1 (en) 2017-01-05
HK1226066A1 (zh) 2017-09-22
IL259738A (en) 2018-07-31
JP6182209B2 (ja) 2017-08-16
CA3055660A1 (en) 2013-12-12
DK2858985T3 (en) 2018-05-28
DK3348553T3 (da) 2020-07-27
RS60617B1 (sr) 2020-09-30

Similar Documents

Publication Publication Date Title
CY1123427T1 (el) Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn
CY1121511T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
CY1120159T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
UY35678A (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGO NISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENÉRGICO
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
UY35177A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
ECSP12012083A (es) Pirrolidina-2-carboxamidas sustituidas
ECSP12011692A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
GT201500159A (es) Derivados de imidazopiridazina como moduladores del receptor gabaa
CR20170035A (es) Compuestos de imidazopiridazina
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
GT201600004A (es) Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h- pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparación, y las formulaciones farmacéuticas que la contienen
EA201690236A1 (ru) Производные индол-3-карбинола
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
ECSP12012120A (es) Compuestos de pirazol como antagonistas de crth2.
CR20120083A (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurologicos
CU24047B1 (es) Derivados de oxazina útiles en el tratamiento de los trastornos neurológicos
TR201106004A2 (tr) Sefalosporin türevinin farmasotik bir bileşim içerisinde kullanımı.